Hagit Shoffel-Havakuk1, Katherine L Marks2, Mariah Morton3, Michael M Johns4, Edie R Hapner4. 1. Department of Otolaryngology Head and Neck Surgery, Rabin Medical Center, Petach Tikva; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 2. Center for Laryngeal Surgery and Voice Rehabilitation, Massachusetts General Hospital, Boston, Massachusetts. 3. Division of Communication Sciences and Disorders, College of Health Sciences, University of Kentucky, Lexington, Kentucky. 4. USC Voice Center, Department of Otolaryngology Head and Neck Surgery, University of Southern California, Los Angeles, California, U.S.A.
Abstract
OBJECTIVES: To establish the validity of the OMNI Vocal Effort Scale (OMNI-VES) for resistance exercise, a single-question pictorial scale, in voice-related perceived exertion. Additionally, the study aimed to assess the role of the OMNI-VES as an outcome measurement in the treatment of adductor spasmodic dysphonia (ADSD). METHODS: A prospective validation study was conducted on 226 participants. The case group was comprised of 178 patients receiving botulinum toxin (BTX) injections for ADSD and 48 controls without a voice disorder. Prior to a planned injection, the participants were asked to complete the OMNI-VES and the Voice-Related Quality-of-Life (V-RQOL) questionnaires, and the clinician completed the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V). A subgroup of 17 patients were administered a repeat assessment 1 month after injection. RESULTS: There was a weak correlation between the OMNI-VES and the V-RQOL score (Tau-b = -0.252, P < 0.001), and no significant correlation with the CAPE-V. Participants with ADSD had significantly higher OMNI-VES scores compared with normal controls, 5.07 ± 2.18 and 1.47 ± 2.28, respectively (P value < 0.0001). The average OMNI-VES score significantly improved 1 month following a BTX injection, from 6 ± 2.4 to 3.4 ± 2.8 (P value = 0.0003). Eighty-eight percent of the patients demonstrated a decrease in the OMNI-VES score following injection, whereas only 47% demonstrated an improvement in the V-RQOL score. CONCLUSION: The OMNI-VES is a validated tool for rating perceived voice-related exertion in people with ADSD and can be used for evaluating response to BTX injection treatment. LEVEL OF EVIDENCE: 2b Laryngoscope, 129:448-453, 2019.
OBJECTIVES: To establish the validity of the OMNI Vocal Effort Scale (OMNI-VES) for resistance exercise, a single-question pictorial scale, in voice-related perceived exertion. Additionally, the study aimed to assess the role of the OMNI-VES as an outcome measurement in the treatment of adductor spasmodic dysphonia (ADSD). METHODS: A prospective validation study was conducted on 226 participants. The case group was comprised of 178 patients receiving botulinum toxin (BTX) injections for ADSD and 48 controls without a voice disorder. Prior to a planned injection, the participants were asked to complete the OMNI-VES and the Voice-Related Quality-of-Life (V-RQOL) questionnaires, and the clinician completed the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V). A subgroup of 17 patients were administered a repeat assessment 1 month after injection. RESULTS: There was a weak correlation between the OMNI-VES and the V-RQOL score (Tau-b = -0.252, P < 0.001), and no significant correlation with the CAPE-V. Participants with ADSD had significantly higher OMNI-VES scores compared with normal controls, 5.07 ± 2.18 and 1.47 ± 2.28, respectively (P value < 0.0001). The average OMNI-VES score significantly improved 1 month following a BTX injection, from 6 ± 2.4 to 3.4 ± 2.8 (P value = 0.0003). Eighty-eight percent of the patients demonstrated a decrease in the OMNI-VES score following injection, whereas only 47% demonstrated an improvement in the V-RQOL score. CONCLUSION: The OMNI-VES is a validated tool for rating perceived voice-related exertion in people with ADSD and can be used for evaluating response to BTX injection treatment. LEVEL OF EVIDENCE: 2b Laryngoscope, 129:448-453, 2019.
Authors: Katherine L Marks; Alessandra Verdi; Laura E Toles; Kaila L Stipancic; Andrew J Ortiz; Robert E Hillman; Daryush D Mehta Journal: Am J Speech Lang Pathol Date: 2021-10-19 Impact factor: 4.018